

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ³ : C12Q 1/38 // C12Q 1/56	A1	(11) International Publication Number: WO 83/ 02123 (43) International Publication Date: 23 June 1983 (23.06.83)
<p>(21) International Application Number: PCT/SE82/00430</p> <p>(22) International Filing Date: 17 December 1982 (17.12.82)</p> <p>(31) Priority Application Number: 8107599-6</p> <p>(32) Priority Date: 17 December 1981 (17.12.81)</p> <p>(33) Priority Country: SE</p> <p>(71)(72) Applicant and Inventor: SÖDERHÅLL, Kenneth, Tord [SE/SE]; Noréns väg 87, S-752 63 Uppsala (SE).</p> <p>(74) Agents: WIDÉN, Björn et al.; Uppsala Patentbyrå, Box 9039, S-750 09 Uppsala (SE).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p>		<p>Published <i>With international search report. In English translation (filed in Swedish).</i></p>
(54) Title: METHOD AND REAGENT FOR DETECTION OF ENDOTOXINES OR β -1,3 GLUCANES FROM FUNGUS OR BACTERIA		
<p>(57) Abstract</p> <p>Method of detecting a fungal or bacterial infection by contacting a sample to be tested with (A) a blood cell lysate from a crustacean or an insect and (B) a detector substance in the form of a peptide compound having a specific terminal group, which through the enzymatic action of a blood cell lysate obtained from such an animal and activated by a bacterium or a fungus may be cleaved off to form a physically or chemically detectable compound. The invention also relates to a reagent or a reagent kit comprising said blood cell lysate and detector substance.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	LI	Liechtenstein
AU	Australia	LK	Sri Lanka
BE	Belgium	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America
KP	Democratic People's Republic of Korea		

METHOD AND REAGENT FOR DETECTION OF ENDOTOXINES OR β -1,3-
GLUCANES FROM FUNGUS OR BACTERIA

The present invention relates to a method and a reagent for detecting bacterial and fungal infections with a high sensitivity.

Various methods for rapidly detecting bacterial infections through Gram-negative bacteria with a relatively high sensitivity are based upon the reaction of a lysate of amebocytes or "blood cells" from horseshoe crabs. The lysate reacts to bacterial endotoxins, which are lipopolysaccharides, such that a gel is formed. This gel phenomenon, which is a defense reaction of the horseshoe crab, is elicited by the lipopolysaccharides activating a serine protease, which in turn converts coagulogen into coagulin. The previous determination methods are based, on one hand, on the gel reaction itself, such as measurement of the gel formation rate, turbidity changes, etc., and, on the other hand, upon the activated serine protease. The last mentioned method, which is the definitely most sensitive one and permits detection of concentrations as low as 10^{-6} - 10^{-9} mg/ml, utilizes the capability of the serine protease to enzymatically hydrolyze certain synthetically prepared polypeptides, such that specific end groups are cleaved off and thereby form compounds which may be detected colorimetrically or fluorometrically. This method is described in, for example, the German Offenlegungsschrift 2,740,323. A commercial reagent, marketed by Kabi Peptide Research Ltd., Mölndal, Sweden, contains a synthetic peptide having a terminal p-nitroanilide group and a lysate from the American horseshoe crab or *Limulus polyphemus*. On addition of bacterial lipopolysaccharides the serine protease of the lysate is activated and the yellow colour of the p-nitroaniline released thereby may be read colorimetrically.

While the above described reaction applies to blood cell lysates from all horseshoe crab species, there is only a small number of living species of this early, almost fossile marine animal. Among those the above horseshoe crab, *Limulus polyphemus*, which exists along the American Atlantic coast, and the Japanese horseshoe crab, *Tachypleus tridentatus*, may be mentioned. These animals, which thus are relatively rare in the oceans, are also becoming depleted, and this is particularly the case for *Limulus polyphemus* which is the one that has so far been most utilized commercially for the above mentioned test method. Since the horseshoe crab cannot be cultured in an aquaculture, a shortage of such lysate may be expected in the future.

Till now there has, however, been no substitute for the blood cell lysate of the horseshoe crab, the horseshoe crab being regarded as an old and primitive



odd branch of the articulates or arthropods with a unique blood system which in several respects differs substantially from those of other arthropods. The above mentioned endotoxin reaction has therefore been believed to be limited to this specific animal species. Thus, for example, the horseshoe crab only has one type
5 of blood cells, while the other arthropods have three to nine distinct blood cell types depending on class and species. A more important difference in this connection is, however, that the coagulogen of the horseshoe crab is in the blood cells, while in other arthropods it has been shown to be included in the plasma, where the main coagulation reaction also takes place. Both plasma and
10 blood cells would therefore be required for a coagulation activation in the latter case, which thus would make the preparation of a fairly stable activable preparation like that from the horseshoe crab impossible.

According to the invention it has, however, been found, that coagulogen and at least one serine protease are included in the blood cells of the arthropods
15 crustaceans and insects and are involved in the activation of a coagulation-like reaction in a similar way as in the horseshoe crab, and that therefore both bacterial and fungal infections may be determined qualitatively as well as quantitatively using a blood cell or hemocyte lysate from these animals. A lysate from these arthropods is activated quantitatively by lipopolysaccharides,
20 or LPS, i.e. bacterial endotoxin, as well as by another type of carbohydrates, viz. β -1,3-glucans, which are part of the cell walls of essentially all fungi. While the biochemical mechanism is not completely known, the β -1,3-glucans very specifically activate a serine protease which, in addition to converting coagulogen into coagulin, converts prophenoloxidase into the active enzyme
25 phenoloxidase.

According to the invention a fungal or bacterial infection may thus rapidly and easily be detected by, in a per se known manner, contacting a sample to be examined with, on one hand, a blood cell lysate from crustaceans or insects, or an activable serine protease or proteases isolated therefrom, and, on
30 the other hand, a detector substance which through the enzymatic action by such a blood cell lysate activated by a bacterial or fungal extract may form a physically or chemically detectable compound, and determining the latter. A corresponding reagent or reagent kit for detecting or determining fungal or bacterial infections therefore comprises, on one hand, a blood cell lysate from
35 crustaceans or insects and, on the other hand, such a detector substance.

Although generally blood cell lysates from all crustaceans and insects could be used according to the invention, among the crustaceans (Crustacea) the




ten-footed crustaceans or the so-called decapods are preferred. Fresh-water decapods as well as marine decapods may be used. As examples of fresh-water crayfish may be mentioned *Astacus astacus* (river crayfish), *Pacifastacus leniusculus* (signal crayfish), *Astacus pallipes*, *Orconectes limosus*, *Astacus* 5 *leptodactylus*, *Cambarus affinis* (North-American crayfish), *Procambarus clarkii*. Among suitable marine decapods *Cancer pagurus* (common or edible crab), *Carcinus maenas* (shore crab), *Homarus vulgaris* (lobster), *Palinurus vulgaris* (spiny lobster), *Nephrops norvegicus* (Norwegian lobster), *Callinectes sapidus* may be mentioned. Among these crustaceans several are directly suited for 10 culturing in an aquaculture, e.g. river crayfish and signal crayfish, but also lobster and crab, and these are therefore preferred for the purposes of the invention.

Among insects particularly those of Orthoptera and Lepidoptera (butterflies) may be mentioned. Examples of the first mentioned order are 15 *Schistocerca gregaria* (desert locust) and *Locusta migratoria* (common locust). Among butterflies *Galleria melonella* (wax-moth), *Hyalphora cecropia* and *Bombyx mori* (silk-moth) may be mentioned. Although insects probably would not be of the same interest for lysate production as crustaceans, the culture of, for example, silk-moth for this purpose might very well be contemplated.

20 Due to the fact that blood cell lysates from, e.g., the above mentioned crustaceans may be used, a simple and continuous source of blood cell lysates having a very uniform quality is assured, since hemolymph from, e.g., crayfish may be collected during the major part of the year. The hemolymph of the horseshoe crab, on the other hand, may only be collected during a very limited 25 period of time.

As mentioned above the coagulation process for hemolymph from crustaceans and insects involves activation of at least one serine protease. Due to the presence of such an active serine protease essentially the same type of peptide compounds, which have been used or suggested for the previously known 30 *Limulus* lysate process, may be used. Thus, the invention comprises a method and a reagent, wherein the detector substance, i.e. the substance to be affected by the activated lysate, is a peptide compound of the formula



wherein R_1 is a peptide moiety protected at the N-terminal and having at least two 35 amino acid units, X is Gly or Ala, preferably Gly, and R_2 is a residue attached to the C-terminal of the arginine residue represented by Arg through an amide and/or ester linkage, and which in the presence of the blood cell lysate



activated by bacteria or fungi may be hydrolyzed enzymatically into R_2H , and/or a mineral acid salt thereof. The residue R_2 is further such that the compound R_2H formed may be detected physically or chemically, e.g. colorimetrically or spectrophotometrically, and is preferably a fluorogenic or a chromogenic compound. Preferably, the group R_2 is derived from p-nitroanilide, 5-nitro- α -naphthylamide, β -naphthylamide, α -naphthyl ester, β -naphthyl ester, indoxyl ester, N-methylindoxyl ester, (4-methyl)umbelliferyl ester and/or resorfin ester, the corresponding compounds R_2H being p-nitroaniline, 5-nitro- α -naphthylamine, β -naphthylamine, α -naphthol, β -naphthol, indoxyl, N-methylindoxyl, 4-methyl-umbelliferon and resorfin. Of these the first two compounds are chromogenic, while the other are fluorescent compounds.

Suitable protecting groups for R_1 are, for example, benzoyl, acetyl, carbobensoxy, tert-butoxycarbonyl and p-toluenesulfonyl.

Particularly suitable peptide derivatives for use in this aspect of the invention are

Bz-Ile-Glu-Gly-Arg-PNA.HCl

Bz-Ile-Glu(γ -piperidyl)-Gly-Arg-PNA.HCl

Bz-Ile-Glu(O-Et)-Gly-Arg-PNA.HCl

Bz-Ile-Glu(O-i-Pr)-Gly-Arg-PNA.HCl

Bz-Ile-Ser-Gly-Arg-PNA.HCl

Bz-Ile-Glu(O-Me)-Gly-Arg-PNA.HCl

wherein Bz = benzoyl, Ac = acetyl, Me = methyl, Et = ethyl, i-Pr = isopropyl and -PNA = p-nitroanilide, and the amino acids are given with the IUPAC abbreviations.

Some of the peptide compounds are commercially available while the others may be prepared with known methods.

In other respects the process may be effected as is described for the Limulus lysate method in the above mentioned German Offenlegungsschrift 2,740,323.

A hemocyte lysate, i.e. a blood cell lysate, from crustaceans and insects according to the invention may be prepared essentially in the same way as the well known Limulus lysate from the horseshoe crab. This method is well described previously in the literature and need therefore not be described in any detail herein. Thus, a partially purified hemocyte lysate from, for example, crustaceans is prepared by first collecting blood from the animal, care being taken to avoid contamination of the blood. It is to be noted that it is not necessary to kill a crustacean which can be cultured in an aquaculture, such as



- 5 -

crayfish, signal crayfish, etc., when collecting the blood, but blood may be collected from the same animal several times at regular intervals as with a human blood donor. This is, of course, a great advantage, since the recovery of blood for hemocyte lysate production according to the invention may then be
5 combined with crayfish culture for food purposes. The hemocytes or blood cells are then isolated through centrifuging and washing in conventional manner. After that they are homogenized in a buffer with a high calcium ion concentration, centrifuged at about 70,000 g and the supernatant recovered. The lysate obtained is more stable than the present commercial lysates from
10 horseshoe crabs and will remain stable for at least 24 hours. Preferably, however, the supernatant obtained is freeze-dried to be diluted with water or a suitable buffer (pH ~ 8) at the time of use. The solution may optionally be stabilized with 0.5 - 1.5M NaCl, whereby a stability of several days may be achieved. Also a solution of the freeze-dried lysate is stable for at least
15 5 hours. To increase the freeze-drying stability, e.g., bovine serum albumin and/or glycine may be added.

A reagent or reagent kit according to the invention for detecting fungal and bacterial infections may comprise a blood cell lysate prepared as above and a detector substance according to the previous definition. Preferably, the lysate
20 and the detector substance are in powder form. When using it for testing, for example, an extract having a suspected fungal or bacterial infection, the test reagent is dissolved in a suitable buffer (pH ~ 8), and then the extract to be tested is added. The reagent solution is then studied, for example, spectrophotometrically or colorimetrically depending on the detector substance used.

25 The method and the reagent of the invention are, in comparison with the horseshoe crab lysate known for endotoxin determination, also extremely sensitive for detecting fungal infections. All fungi containing β -1,3-glucans in the cell walls thereof may be detected, which applies to all existing fungi with few exceptions. To rapidly be able to detect fungal infections in accordance with
30 the invention is of great value. At present, fungal skin infections on humans and animals are cultured, which takes about 2 weeks. Also, mould infections in food, so-called mycotoxins, are becoming a rapidly increasing problem.

The sensitivities hitherto obtained with the use of lysates from crustaceans according to the invention are about 10^{-8} - 10^{-9} g/ml to endotoxins
35 (bacterial infection) and about 10^{-10} g/ml to β -1,3-glucans (fungal infection). The sensitivity to endotoxins may probably be increased further by eliminating inhibitors of the endotoxin activation which have been shown to be included in



the lysate, for example analogously to what is now done with the commercial horseshoe crab lysates.

The blood cell lysates may be rendered endotoxin specific by adding an excess of β -1,3-glucans. In a corresponding manner β -1,3-glucan specificity may be achieved by adding anti-endotoxin factors, produced in pure form from crayfish lysate, which will then prevent the endotoxin activation of the crayfish lysate. Alternatively, high contents of endotoxin (LPS) may be added.

Quantitative determinations of endotoxins and β -1,3-glucans, respectively, by means of the inventive process may be effected in a manner known per se, e.g. by providing a standard or calibration curve.

The invention will now be described in more detail by means of some specific examples, which, however, are not limiting to the invention in any way.

Example 1

Preparation of a hemocyte lysate

15 Hemocytes from crayfish, *Astacus astacus*, were collected as described in Söderhäll, K., Häll, L., Unestam, T., and Nyhlén, L. (1979) *J. Invertebr. Pathol.* 34, 285-294, except that 0.1M sodium citrate was excluded. The hemocytes were homogenized in 10 mM sodium cacodylate buffer, pH 7.0, with 100 mM CaCl_2 and the homogenate was then centrifuged for 20 minutes at 20 70,000 g. The supernatant obtained, containing approximately 2 mg protein/ml, may be used either immediately or freeze-dried in 3 ml aliquots. Prior to use it is dissolved in 3 ml of distilled water to a final protein concentration of 2 mg/ml.

Example 2

β -1,3-glucan activation of crayfish hemocyte lysate

25 In order to test the method of the invention with regard to specific β -1,3-glucan activation of the hemocyte lysate, two volumes of the hemocyte lysate from Example 1 were mixed with one volume of β -1,3-glucans or other carbohydrates of the concentrations given in the following Table 1 for 30 30 minutes at 20-22°C. 100 μ l of this reaction mixture was added to 600 μ l of 0.1M tris-HCl-buffer, pH 8.0, and 100 μ l of a 2 mM solution of the synthetic peptide Bz-Ile-Glu(γ -piperidyl)-Gly-Arg-PNA.HCl (obtained from Kabi Peptide Research Ltd., Mölndal, Sweden). After incubation for 0.5 hour at 37°C 100 μ l of 50% acetic acid were added to terminate the reaction, and the released p- 35 nitroaniline (PNA) was measured spectrophotometrically at 405 nm.

The β -1,3-glucans used were Zs (the supernatant of a 1% suspension of yeast cell walls, Zymosan, Sigma), laminaran M, laminaran G and a linear pentasaccharide composed of β -1,3-D-linked glucosyl residues. Laminaran M and



G were purified from laminaran (Sigma) by using DEAE-molybdate-Sephadex[®] chromatography according to Stark S., J.R. (1976) Carbohydr. Res. 47, 176-178. The linear pentasaccharide was prepared and purified as described in Söderhäll, K., and Unestam, T. (1979) Can. J. Microbiol. 25, 406-414.

5 The results of the enzyme activity determination (serine protease) showing the specific β -1,3-glucan activation appears from Table 1 below.



Table 1
 β -1,3-glucan activation of serine protease in crayfish hemocyte lysate

Glucan	Structure	Degree of polymerisation	Concentration (glucose equiv., μ g/ml)	Enzyme activity ($\Delta A_{405}/30$ min)
None	-	-	0	0.03
Zymosan supernatant	(1 \rightarrow 3) β -D-glucan with β -1,6-linkages	varying ⁴ ($2 \cdot 10^4 - 10^6$)	60	0.85
Laminaran M	(1 \rightarrow 3) β -D-glucan ended with mannitol	20	300	0.99
Laminaran G	(1 \rightarrow 3) β -D-glucan ended with glucose	20	300	0.99
Laminara-pentaose	(1 \rightarrow 3) β -D-glucan	5	300	0.95
Other carbohydrates tested ^x			300-1600	not detected

^x Other carbohydrates tested were chitin, cellulose, dextran, glucose and mannitol.



Example 3

Freeze-dried hemocyte lysate from Example 1 was dissolved in 3 ml of 0.1 M tris-HCl-buffer of pH 8.0. This solution was then mixed with 1.5 ml of Zymosan supernatant according to Example 2 and incubated for 30 minutes at 20°C. From this reaction mixture 100 µl were withdrawn and added to 600 µl of 0.1 M tris-HCl (pH 8.0). 100 µl of 2 mM solutions of different synthetic peptides having chromogenic terminal groups (obtained from Kabi Peptide Research Ltd., Mölndal, Sweden) were added to this mixture, and after incubation for 1 hour at 37°C the reaction was terminated by adding 100 µl of 50% acetic acid. The released p-nitroaniline was then measured spectrophotometrically at 405 nm. The results for the different chromogenic substrates are listed in Table 2 below.

Table 2

Hydrolysis of different chromogenic substrates by preactivated crayfish hemocyte lysate

15	Chromogenic substrate	Enzyme activity ($\Delta A_{405}/30 \text{ min}$)
	Bz-Ile-Glu-Gly-Arg-PNA.HCl	0.62
	Bz-Ile-Glu(γ -piperidyl)-Gly-Arg-PNA.HCl	0.84
	Bz-Ile-Glu(O-Et)-Gly-Arg-PNA.HCl	0.84
20	Bz-Ile-Glu(O-i-Pr)-Gly-Arg-PNA.HCl	0.92
	Bz-Ile-Ser-Gly-Arg-PNA.HCl	0.90
	Bz-Ile-Glu(O-Me)-Gly-Arg-PNA.HCl	0.70

Example 4

A reagent according to the invention consisting of a crayfish hemocyte lysate according to Example 1 in 0.01 M cacodylate buffer (pH 7.0) and an equal amount (about 100 µl) of Bz-Ile-Glu(γ -piperidyl)-Gly-Arg-PNA.HCl were mixed with pre-heated (5 minutes, 100°C) extracts of the following fungi: *Aphanomyces astaci*, *Aphanomyces laevis*, *Aphanomyces euteiches*, *Saccharomyces cerevisiae*, *Aspergillus flavus*, *Penicillium viridicatum*, *Candida albicans*, *Polyporus annosus*, *Boletus variegatus*. The solutions were then observed colorimetrically at 405 nm. For all the fungi a yellow colour was obtained indicating activation of the hemocyte lysate with associated enzymatic hydrolysis of the p-nitroanilide group to p-nitroaniline.

Example 5

35 A mixture of 100 µl of hemocyte lysate from Example 1, 100 µl of *E. coli* endotoxin (Mallinckrodt, Inc., USA) of different concentrations, 100 µl of



0.1 M tris-HCl, pH 8.0, and 100 μ l of a 2 mM solution of Bz-Ile-Glu(γ -piperidyl)-Gly-Arg-PNA.HCl (from Kabi Peptide Research Ltd., Mölndal, Sweden) were incubated for 30 minutes at 37°C. 100 μ l of 50% acetic acid were then added to terminate the reaction, and the released p-nitroaniline was measured spectrophotometrically at 405 nm. The absorbance changes obtained appear from Table 3:

Table 3

	Endotoxin concentration g/ml	$\Delta A_{405}/30 \text{ min}/100 \mu\text{l}$ hemocyte lysate
10	1×10^{-6}	0.64
	1×10^{-7}	0.55
	1×10^{-8}	0.18
	1×10^{-9}	0.058
	Control	0.030

15

Example 6

In analogy with Example 1 hemocyte lysates were prepared from the following crustaceans:

Pacifastacus leniusculus

Astacus pallipes

20

Astacus leptodactylus

Orconectes limosus

Cancer pagurus

Carcinus maenas

Nephrops norvegicus

25


The lysates obtained were tested for activation by β -1,3-glucans and endotoxins in analogy with the methods described in Examples 2 and 5, activation (release of p-nitroaniline) being indicated for all the lysates.

Blood cell lysates from the insects Schistocerca gregaria, Galleria melonella, Hyalophora cecropia and Bombyx mori have so far only been tested with regard to activation of phenoloxidase, which, as for the above mentioned crustacean lysates, gave positive results. Because of the great similarities between the blood systems of crustaceans and insects, and since it was found in connection with the invention that phenoloxidase in turn is activated by a serine protease, also these insect lysates must be expected to be activated in testing as above.



CLAIMS

1. A method for detecting fungi and/or bacteria by detecting or determining endotoxins and β -1,3-glucans, respectively, characterized by contacting the sample to be tested with (A) a blood cell lysate from an animal belonging to one of the arthropod classes crustaceans (Crustacea) and insects (Insecta), or an activable serine protease or proteases isolated therefrom, and (B) a detector substance in the form of a peptide compound of the formula



- wherein R_1 is a peptide moiety protected at the N-terminal thereof and having at least 2 amino acid units, X is Gly or Ala, and R_2 is a residue attached to the C-terminal end of the arginine residue represented by Arg through an acid amide and/or ester linkage and which in the presence of the blood cell lysate activated by endotoxin or β -1,3-glucan is capable of being enzymatically hydrolyzed to R_2H , and/or a mineral acid salt thereof, and determining the R_2H formed, R_2H being such a compound that may be detected physically or chemically, preferably a fluorogenic or chromogenic compound.

2. A method according to claim 1, characterized in that the blood cell lysate is a hemocyte lysate from an animal belonging to the order of decapods.

3. A method according to claim 2, characterized in that the hemocyte lysate is derived from a fresh-water crayfish, particularly *Astacus astacus* or *Pacifastacus leniusculus*.

4. A method according to claim 2, characterized in that said decapod is selected from *Astacus astacus*, *Pacifastacus leniusculus*, *Astacus leptodactylus*, *Astacus pallipes*, *Orconectes limosus*, *Cambarus affines*, *Procambarus clarkii*, *Cancer pagurus*, *Carcinus maenas*, *Homarus vulgaris*, *Palinurus vulgaris*, *Nephrops norvegicus* and *Callinectes sapidus*.

5. A method according to any one of claims 1 - 4, characterized in that R_2 is a p-nitroanilide, 5-nitro- α -naphthylamide, β -naphthylamide, α -naphthyl ester, β -naphthyl ester, indoxyl ester, N-methylindoxyl ester, (4-methyl)umbelliferyl ester or resorfin ester group.




- 12 -

6. A method according to any one of claims 1 - 5,
characterized in that the detector substance is selected from
- Bz-Ile-Glu-Gly-Arg-PNA.HCl
Bz-Ile-Glu(γ -piperidyl)-Gly-Arg-PNA.HCl
5 Bz-Ile-Glu(O-Et)-Gly-Arg-PNA.HCl
Bz-Ile-Glu(O-i-Pr)-Gly-Arg-PNA.HCl
Bz-Ile-Ser-Gly-Arg-PNA.HCl
Bz-Ile-Glu(O-Me)-Gly-Arg-PNA.HCl
Ac-Ile-Glu-Ala-Arg-PNA.HCl
- 10 wherein Bz is benzoyl, Ac is acetyl and -PNA is p-nitroanilide.
7. A reagent for detecting fungi and/or bacteria by detecting or
determining endotoxins and β -1,3-glucans, respectively,
characterized by comprising (A) a blood cell lysate from an animal belonging to
one of the arthropod classes crustaceans (Crustacea) and insects (Insecta), and
15 (B) a detector substance as defined in claim 1, 5 or 6.
8. A reagent according to claim 7 for detecting a fungal infection,
characterized by comprising at least one anti-endotoxin factor or an excess of
endotoxin.
9. A reagent according to claim 7 for detecting a bacterial infection,
20 characterized by comprising an excess of β -1,3-glucan.
10. A reagent according to any one of claims 7 - 9,
characterized by comprising a blood cell lysate as defined in any one of claims 2
- 4.



INTERNATIONAL SEARCH REPORT

International Application No PCT/SE82/00430

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC 3		
C 12 Q 1/38 // C 12 Q 1/56		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC 3	C 12 Q 1/00, 34, 36, 38, 56	
US C1	435:4, 13, 23; 195:103.5	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
SE, NO, DK, FI classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT 14		
Category *	Citation of Document, 15 with indication, where appropriate, of the relevant passages 17	Relevant to Claim No. 18
A	US, A, 4 301 245 (LINDSAY G AND O'BEIRNE A J) 17 November 1981	1-10
A	DE, B2, 2 740 323 (SEIKAGAKU KOGYO CO LTD) 25 October 1979	1-10
A	EP, A3, 0 041 089 (DYNASCIENCES CORPORATION) 9 December 1981	1-10
E	EP, A3, 0 056 210 (PHARMINDUSTRIE) 21 July 1982 & WO, A, 82/02382	1-10
A	Patent Abstracts of Japan, Vol 5, No 102, C61, abstract of JP 56-42597, publ. 1981-04-20.	1-6
A	Chemical Abstracts Vol 94(1981), abstract No 2223q, FEBS Lett. 1980, 120(2), 217-20.	1
A	Chemical Abstracts Vol 94(1981), abstract No 151160u, Progr. Clin. Biol. Res. 1979, 29, 209-20. .../...	1
<p>* Special categories of cited documents: 19</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 1	Date of Mailing of this International Search Report 1	
1983-02-25	1983-03-02	
International Searching Authority 1	Signature of Authorized Officer 20	
Swedish Patent Office	 C-O Gustafsson	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
A	Chemical Abstracts Vol 95(1981), abstract No 181776n, Clin. Chim. Acta 1981, 116(1), 63-8.	1
E	Chemical Abstracts Vol 96(1982), abstract No 83106v, Dev. Comp. Immunol. 1981, 5(4), 565-73.	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/02878

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(5) :G06F 15/62
 US CL :395/159,161,153
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 395/144-147,156,157,158,160; 340/716,721,723

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 APA-USPAT - E MAIL, DOCUMENT (4A) COLLECTION, COMPUTER FILING, DOCUMENT (4A) ICON, GRAPHICAL USER INTERFACE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,885,704 (TAKAGI ET AL.) 05 December 1989, See figure 9 and column 5-6.	1-72
Y	US, A, 5,060,135 (LEVINE ET AL.) 22 October 1991, See the entire document.	1-72
A,P	US, A, 5,140,677 (FLEMING ET AL.) 18 August 1992, See the entire document.	1-72

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be part of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 31 MAY 1993	Date of mailing of the international search report 14 JUL 1993
--	---

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer HEATHER HERNDON Telephone No (703) 305-9797
---	--

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

